No one is attacking you personally.
We just feel like you are trying to set us up with the seemingly harmelss and naively innocent questions you are asking.
If you want a straight answer let me give you one. Investing in Biotech's is extremely risky and even more so since there is a history of short manipulation that is some cases have helped push fragile new-starts to bankruptcy. NBWO is not different and probably even more risky.
Now with that said us longs see something potentially remarkable with DCVAX both L and Direct. It has the potential to treat GBM and other untreatable cancers where patients have no other viable treatments and their prospects and life expectancy are bleak. If you go back several years there are animal studies, early phase trials and info arm data (very sick patients that did on qualify for the trial) that show remarkable, extraordinary results. The FDA thought Direct was so promising they approved trials for "all" inoperable solid tumor cancers. Who has ever heard of that happening before. At the same time Big Pharma looks at this and are frightened. They are in the very profitable business of mass producing treatments (a single pill or injection) that any patients can take. The last thing they want is to move to a business where every treatment has to be personalized (draw blood, send tumor tissue for L, cultivate DCs' create treatments, etc . . .). This will completely disrupt the industry but us longs believe it also has the potential to cure many forms of currently incurable cancers that are a death sentence . . . but there a lot of very powerful parties that want to see NWBO fail.
SO . . . that is where most of the long time longs are and we are not interested in you dragging us into completely speculative questions about LP motives, mismanagement of the company, stealing money funnel to Cognate, lack of communication, negotiation with Merck or BMS, is it a halt or screening halt, status of the investigation and if DCVAX is really no more effective than a slurry of grapefruit juice . . . soon enough we believe we will get approval for DCVAX L, at least for Mesenchyma Subgroup patients where it appears to be a cure . . . and that will hopefully make all the difference . . . we'll see. Keep your fingers crossed.
